DPP4 and type 2 diabetes mellitus: Therefore, more research is needed in order to evaluate the efficacy and safety profile of incretin mimetics and DPP-4 inhibitors as add-on therapies for type 2 diabetes in other ethnic groups in the Asia-Pacific region as different ethnicities might have different pharmacological responses to these novel agents.